COLORADO SPRINGS, CO – Cannabis Science, Inc. (OTC PINK: CBIS), a U.S. company specializing in the development of cannabis-based medicines, today announced they have taken another step to improve the company’s bottom line for United States cannabinoid pharmaceutical drug development programs.
The Company also announced its new toll-free number 1-888-263-0832, as the President phone line has been inundated with cheer over the gifted share program. Please call the new number to ensure your information is documented. Once the Company website has been updated, a news release will point everyone in the right directions.
The Cannabis Science 360,000 Sq. Ft. Nevada pharmaceutical drug development compound is currently going through design phase; it will also include a University for higher educational curriculums, medicinal practice, and laboratory research.
The Nevada Compound presents an additional opportunity of over 900,000 Sq. Ft., for investment tender to the qualified public. The land is currently being partitioned into 1 Acre parcels that will allow for up to 36,000 Sq. Ft. each acre for cannabis cultivation, extract product development & research, fully licensed and state compliant.
The Company has now identified its next property development in the State of California, as it works through the paperwork; the Nevada development grows with more investors and entrepreneurs looking to capitalize and expand in the Nevada sector of the Cannabis Industry.
“This business model of building very large cannabis industry complexes has grown so fast for us it is literally spellbinding,” stated President & CEO Raymond C. Dabney. “The opportunity presented itself and we seized the moment. That swift move has placed us in the formidable position to become one of the premier Companies providing education, medical facilities, and laboratories across the Country on some very large land parcels.
“The Nevada design phase is certainly underway and property lines and parcels are being completed. To be able to offer such a large amount of land coupled with the opportunity to other likeminded firms and individuals is a blessing on its own; to own a major piece of the operations is for Cannabis Science the landmark breakthrough we have been waiting for. This certainly changes the face of Cannabis Science.
“We have been negotiating with entrepreneurs and companies of various sizes and packages, on five-acre, three-acre, and one-acre parcels; at this rate we are confident filling these opportunities will not take long. For those that have the vision and believe that medical cannabis is the future, this partnership program enables them to be involved right now. The advancements in medical cannabis are virtually infinite. We are hearing from people that are looking for a ground floor opportunity as this industry is still in its infancy,” concluded Dabney.
About Cannabis Science, Inc.
Cannabis Science, Inc., takes advantage of its unique understanding of metabolic processes to provide novel treatment approaches to a number of illnesses for which current treatments and understanding remain unsatisfactory. Cannabinoids have an extensive history dating back thousands of years, and currently, there are a growing number of peer-reviewed scientific publications that document the underlying biochemical pathways that cannabinoids modulate. The Company works with leading experts in drug development, medicinal characterization, and clinical research to develop, produce, and commercialize novel therapeutic approaches for the treatment for illnesses caused by infections as well as for age-related illness. Our initial focus is on skin cancers, HIV/AIDS, and neurological conditions. The Company is proceeding with the research and development of its proprietary drugs as a part of this initial focus: CS-S/BCC-1, CS-TATI-1, and CS-NEURO-1, respectively.
This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing words such as “anticipate,” “seek,” intend,” “believe,” “estimate,” “expect,” “project,” “plan,” or similar phrases may be deemed “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company’s reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc., does not undertake any duty nor does it intend to update the results of these forward-looking statements. Safe Harbor Statement. The Private Securities Litigation Reform Act of 1995 provides a ‘safe harbor’ for forward looking statements. Certain of the statements contained herein, which are not historical facts are forward looking statements with respect to events, the occurrence of which involved risks and uncertainties. These forward- looking statements may be impacted, either positively or negatively, by various factors. Information concerning potential factors that could affect the company are detailed from time to time in the company’s reports filed with the Securities and Exchange Commission.
- Cannabis Science Inc.
Tel: 1-888-263-0832Cannabis Science, Inc.
Mr. Raymond C. Dabney
President & CEO, Co-Founder
Cannabis Science, Inc.
Mr. Robert Kane
Director & CFO